Paal F. Brunsvig
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Journal: Journal for immunotherapy of cancer
Published: April 14, 2022
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Journal: Frontiers in immunology
Published: February 03, 2021
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2020
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Journal: Frontiers in immunology
Published: June 12, 2020
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
Journal: Clinical and experimental immunology
Published: February 20, 2019
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
Journal: Anticancer research
Published: November 20, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 20, 2017
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: October 20, 2016
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 24, 2016
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Journal: Acta oncologica (Stockholm, Sweden)
Published: October 24, 2015
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
Journal: Cancer immunology, immunotherapy : CII
Published: June 30, 2015
Last Updated: 09/26/2026